Nicox (NICXF) Other Stockholders Equity : $8.02 Mil (As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Nicox Other Stockholders Equity?

Nicox's Other Stockholders Equity for the quarter that ended in Jun. 2023 was $8.02 Mil.

Nicox's quarterly Other Stockholders Equity declined from Jun. 2022 ($8.13 Mil) to Dec. 2022 ($8.12 Mil) and declined from Dec. 2022 ($8.12 Mil) to Jun. 2023 ($8.02 Mil).

Nicox's annual Other Stockholders Equity increased from Dec. 2020 ($3.60 Mil) to Dec. 2021 ($6.72 Mil) and increased from Dec. 2021 ($6.72 Mil) to Dec. 2022 ($8.12 Mil).

Nicox Other Stockholders Equity Historical Data

The historical data trend for Nicox's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Other Stockholders Equity Chart

Nicox Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Other Stockholders Equity

Get a 7-Day Free Trial

7.62

8.68

3.60

6.72

8.12

Nicox Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Other Stockholders Equity	Get a 7-Day Free Trial															5.54	6.72	8.13	8.12	8.02

Nicox Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Nicox Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Nicox's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox (NICXF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (OTCPK:NICXF) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

ALCOX:France NXOA:Germany

Address

2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560

Website

https://www.nicox.com

Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (NICXF) Headlines

From GuruFocus

Bausch Health Announces VYZULTA� (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in South Korea

By PRNewswire PRNewswire • 02-09-2021